Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus probiotic cocktail
- Development stage
- Preclinical
- Lead developer
- Mashhad University of Medical Sciences
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
The lactobacillus probiotic cocktail is a microbial therapeutic formulation consisting of four specific strains of lactic acid bacteria: *Lactobacillus plantarum*, *Lactobacillus brevis*, *Lactobacillus delbrueckii*, and *Lactobacillus helveticus*. These strains were isolated from traditional dairy products in northeastern Iran. The cocktail is being investigated for its therapeutic potential in treating ulcerative colitis (UC). It functions by modulating the intestinal microbiota, improving intestinal barrier function, and exerting potent anti-inflammatory, antioxidant, and anti-fibrotic effects. Specifically, it has been shown to down-regulate pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6, while up-regulating antioxidant enzymes like superoxide dismutase and catalase. Additionally, it reduces colonic fibrosis by suppressing the expression of pro-fibrotic genes including Acta2 and collagen types Col1a1 and Col1a2.
- Other names
- Lactobacillus cocktailmix of newly isolated probiotics containing L. plantarum, L. brevis, L. delbrueckii, and L. helveticus
02
Targets
COL1A2 (Type I collagen alpha-2 chain)IL-6 (Interleukin 6)NeuraminidaseACTA2 (Alpha-smooth muscle actin)COL1A1 (Collagen type I alpha 1 chain)IFNG (Interferon gamma)TNFA (Tumor necrosis factor alpha (soluble))IL1B (Interleukin-1 beta)
Beyond the preview
Go deeper on lactobacillus probiotic cocktail.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus probiotic cocktail.